Paraoxonase, oxidized low density lipoprotein, monocyte chemoattractant protein-1 and adhesion molecules are associated with macrovascular complications in patients with type 2 diabetes mellitus

Minerva Medica

Volumn 105, Issue 3, 2014, Pages 237-244

  Sozer, V ^a   Himmetoglu, S ^b   Korkmaz, G G ^c   Kaya, S ^b   Aydin, S ^b   Yumuk, V ^b   Hatemi, H ^b   Uzun, H ^b  

^a YILDIZ TECHNICAL UNIVERSITY   (Turkey)

^b ISTANBUL UNIVERSITY   (Turkey)

^c KIRKLARELI UNIVERSITY   (Turkey)

Author keywords

Aryldialkylphosphatase; Chemokine CCL2; Intercellular adhesion molecule 1; Oxidative stress; Oxidized low density lipoprotein

Indexed keywords

APOA1 PROTEIN, HUMAN; APOLIPOPROTEIN A1; ARYLDIALKYLPHOSPHATASE; CCL2 PROTEIN, HUMAN; CELL ADHESION MOLECULE; ICAM1 PROTEIN, HUMAN; INTERCELLULAR ADHESION MOLECULE 1; LOW DENSITY LIPOPROTEIN; MALONALDEHYDE; MONOCYTE CHEMOTACTIC PROTEIN 1; OXIDIZED LOW DENSITY LIPOPROTEIN; PON1 PROTEIN, HUMAN;

ADULT; AGED; ARTICLE; ATHEROSCLEROSIS; BLOOD; DIABETIC ANGIOPATHY; ENZYMOLOGY; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; INFLAMMATION; MALE; METABOLISM; MIDDLE AGED; NON INSULIN DEPENDENT DIABETES MELLITUS; PATHOPHYSIOLOGY; VASCULAR ENDOTHELIUM;

ADULT; AGED; APOLIPOPROTEIN A-I; ARYLDIALKYLPHOSPHATASE; ATHEROSCLEROSIS; BLOOD GLUCOSE; CELL ADHESION MOLECULES; CHEMOKINE CCL2; DIABETES MELLITUS, TYPE 2; DIABETIC ANGIOPATHIES; ENDOTHELIUM, VASCULAR; FEMALE; HUMANS; INFLAMMATION; INTERCELLULAR ADHESION MOLECULE-1; LIPOPROTEINS, LDL; MALE; MALONDIALDEHYDE; MIDDLE AGED;

EID: 84906534754     PISSN: 00264806     EISSN: 18271669     Source Type: Journal    
DOI: None     Document Type: Article

References (36)

1. Calles-Escandon J, Cipolla M. Diabetes and endothelial dysfunction: A clinical perspective. Endocrine Reviews 2001;22:36-52.
2. Blüher M, Unger R, Rassoul F, Richter V, Paschke R. Relation between glycaemic control, hyperinsuline-mia and plasma concentrations of soluble adhesion molecules in patients with impaired glucose tolerance or Type 2 diabetes. Diabetologia 2002;45:210-6.
3. Durrington PN, Mackness B, Mackness MI. Paraoxo-nase and atherosclerosis. Arteroscler Thromb Vase Biol 2001;21:473-80.
4. Mackness MI, Mackness B, Durrington PN, Connelly PW, Hegele RA. Paraoxonase: biochemistry, genetics and relationship to plasma lipoproteins. Curr Opin Lipidol 1996;7:69-76.
5. Mackness B, Mackness MI. Paraoxonase 1: biochemistry and contribution to atherosclerosis. International Congress Series 2004;1262:91-4.
6. Takaishi H, Taniguchi T, Takahashi A, Ishikawa Y, Yokoyama A. High glucose accelerates MCP-1 production via p38 MAPK in vascular endothelial cells. Biochem Biophy Res Commun 2003;305:122-8.
7. Mackness B, Hine D, Liu Y, Mastorikou M, Mackness M. Paraoxonase-1 inhibits oxidised LDL-induced MCP-1 production by endothelial cells. Biochem Biophy Res Commun 2004;318:680-3.
8. Altannavch TS, Roubalova K, Kucera P, Andel M. Effect of high glucose concentrations on expression of ELAM-1, VCAM-1 and ICAM-1 in HUVEC with and without cytokine activation. Physiol Res 2004;53:77-82.
9. Aviram M, Rosenblat M, Bisgaier CL, Newton RS, Primo-Parmo SL, La Du BN. Paraoxonase inhibits high density lipoprotein oxidation and preserves its functions. J Clin Invest 1998;101:1581-90.
10. Tsuzura S, Ikeda Y, Suehiro T, Ota K, Osaki F, Arii K et al. Correlation of plasma oxidized low density lipoprotein levels to vascular complications and human serum paraoxonase in patients with type 2 diabetes. Metabolism 2004;53:297-302.
11. Alberti KG, Zimmet PZ. Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Diabet Med 1998;15:539-53.
12. Buege JA, Aust SD. Microsomal lipid peroxidation. Methods Enzymol 1978;52:302-10.
13. Balci H, Gene H, Papila C, Can G, Papila B, Yanardag H et al. Serum lipid hydroperoxide levels and paraoxonase activity in patients with lung, breast, and colorectal cancer. J Clin Lab Anal. 2012;26:155-60.
14. Friedewald WT, Levy EI, Frederickson DS. Estimation of the consentration of low-density lipoprotein cholesterol in plasma, without use of preparative ultra-centrifuge. Clin Chem 1972;18:499-502.
15. Vucic M, Bozicevic S, Mesic R, Cvitkovic L, Rocic B. An automated immunoturbidimetric assay for HbAlc determination. Clin Chem Lab Med 1999;37:S199.
16. Kuyvenhoven JP, Meinders AE. Oxidative stress and diabetes mellitus, Pathogenesis of long-term complications. Eur J Int Med 1999;10:9-19.
17. Komosinska-Vassev K, Olczyk K, Olczyk P, Winsz-Szczotka K. Effects of metabolic control and vascular complications on indices of oxidative stress in type 2 diabetic patients. Diabetes Res Clin Pract 2005;68:207-16.
18. Mackness MI, Arrol S, Durrington PN. Paraoxonase prevents accumulation of lipoperoxides in low-density lipoprotein. FEBS Lett 1991;286:152-4.
19. Mackness MI, Arrol S, Abbott CA, Durrington PN. Protection of low-density lipoprotein against oxidative modification by high-density lipoprotein associated paraoxonase. Atherosclerosis 1993;104:129-35.
20. Kopprasch S, Pietzsch J, Kuhlisch E, Graessler J. Lack of association between serum paraoxonase 1 activities and increased oxidized low density lipoprotein levels in impaired glucose tolerance and newly diagnosed diabetes mellitus. J Clin Endocrinol Metab 2003;88:1711-6.
21. Beer S, Moren X, Ruiz J, James RW. Postprandial modulation of serum paraoxonase activity and concentration in diabetic and non-diabetic subjects. Nutr Metab Cardiovasc Dis. 2006;16:457-65.
22. Marui N, Offermann MK, Swerlick R, Kunsch C, Rosen CA, Ahmad M etal. Vascular cell adhesion molecule-1 (VCAM-1) gene transcription and regulated through an antioxidant-sensitive mechanism in human vascular endothelial cells. J Clin Invest 1993;92:1866-74.
23. Cominacini L1, Garbin U, Pasini AF, Davoli A, Cam-pagnola M, Contessi GB et al. Antioxidants inhibit the expression of intercellular cell adhesion molecule-1 and vascular cell adhesion molecule-1 induced by oxidized LDL on human umbilical vein endothelial cells. Free Rad Biol Med 1997;22:117-27.
24. Wung BS, Cheng, JJ, Hsich HJ, Shyy YJ, Wang DL. Cyclic strain induced monocyte chemotactic protein-1 gene expression in endothelial cells involves reac-tives oxygen species activation of activator protein 1. Circ Res 1997;81:1-7.
25. Thorand B, Baumert J, Chambless L, Meisinger C, Kolb H, Doring A et al. Elevated markers of endothelial dysfunction predict type 2 diabetes mellitus in middle-aged men and women from the general population. Arterioscler Thromb Vase Biol 2006;26:398-405.
26. Hoogeveen RC, Ballantyne CM, Bang H, Heiss G, Duncan BB, Folsom AR et al. Circulating oxidised low-density lipoprotein and intercellular adhesion molecule-1 and risk of type 2 diabetes mellitus: the Atherosclerosis Risk in Communities Study. Diabeto-logia 2007;50:36-42.
27. Rabini RA, Fumelli P, Galassi R, Dousset N, Taus M, Ferretti G et al. Increased susceptibility to lipid oxidation of low-density lipoproteins and erythrocyte membranes from diabetic patients. Metabolism 1994;43:1470-4.
28. Vicentini J, Valentini J, Grotto D, Paniz C, Roehrs M, Brucker N etal. Association among microalbuminuria and oxidative stress biomarkers in patients with type 2 diabetes. J Investig Med. 2011;59:649-54.
29. Deakin SP, James RW. Genetic and environmental factors modulating serum concentrations and activities of the antioxidant enzyme paraoxonase-I. Clin Sci 2004;107:435-47.
30. Agachan B, YUmaz H, Karaali Z, Isbir T Paraoxonase 55 and 192 polymorphism and its relationship to serum paraoxonase activity and serum lipids in Turkish patients with non-insulin dependent diabetes mellitus.'Cell Biochem Funct 2004;22:63-168.
31. Juretic D, Motejlkova A, Kunovic B, Kunovic B, Rekic B, Flegar-Mestric Z, Vujic L et al. Paraoxonase/ arylesterase in serum of patients with type II diabetes mellitus. Acta Pharm 2006;56:59-68.
32. Dunet V, Ruiz J, Allenbach G, Izzo P, James RW, Prior JO. Effects of paraoxonase activity and gene polymorphism on coronary vasomotion. FJNMMI Res 2011;1:27.
33. Gupta N, Binukumar BK, Singh S, Sunkaria A, Kandimalla R, Bhansali A et al. Serum paraoxo-nase-1 (PON1) activities (PONase/AREase) and polymorphisms in patients with type 2 diabetes mellitus in a North-West Indian population. Gene 2011;487:88-95.
34. Nevin DN, Zambon A, Furlong CE, Richter RJ, Humbert R, Hokanson JE et al. Paraoxonase genotypes, lipoprotein lipase activity, and HDL. Arterioscler Thromb Vase Biol 1996;16:1243-9.
35. Tomas M, Senti M, Garcia-Faria F, Vila J, Torrents A, Covas M et al. Effect of simvastatin therapy on paraoxonase activity and related lipoproteins in familial hypercholesterolemic patients. Arterioscler Thromb Vase Biol 2000;20:2113-9.
36. Papatheodorou K, Papanas N, Papazoglou D, Gioka T, Antonoglou C, Glaros D et al. Monocyte Chemoat-tractant Protein 1 Is Correlated With Glycemic Control and Peripheral Arterial Disease in Type 2 Diabetic Patients With Metabolic Syndrome. Angiology 2013;64:223-9.